Start here: the dose is yours, and only your prescriber sets it Every number on this page is a typical range that Australian prescribers work within. None of it is a recommendation for you.
Two people on the same medicine can be on very different doses and both be right. It depends on your goals, your blood results, your other health conditions, your age, and what your body does with the medicine.
Guidance is explicit that doses are individualised, and that some people — including many non-binary people — deliberately aim for partial effects on a lower dose. Low dose is not no dose, and it is a legitimate goal to raise with your prescriber.
Only a prescriber can set your dose, and only a prescriber should change it Never start, stop, increase or skip a dose on your own If your dose is not working for you, that is a conversation — not a change to make at home Your pharmacist can talk it through with you for free, without an appointment If you are reading this to work out whether your own dose is right, the answer is not on this page. Take the question to your prescriber or your pharmacist.
Oestrogen (estradiol) Estradiol is the oestrogen used in feminising hormone therapy in Australia. It is the same hormone a body makes naturally, given as a medicine.
It comes as tablets, skin patches and skin gel. Which one suits you is a clinical decision, not just a preference.
Patches and gel avoid the first pass through the liver, so they are preferred where the risk of blood clots is higher.
Ethinylestradiol, the oestrogen in the combined pill, is not used for gender affirmation. The high doses used until 1989 were linked to more clots.
Estradiol injections and implants are not available as registered products here. Compounded versions exist, but they are not tested for potency, efficacy, safety or quality control, and Australian guidance advises caution.
Australia's 2026 standards of care say implants are not recommended for starting therapy, but are preferred by many people for maintenance, once treatment is settled. They often give higher oestradiol levels. They come only from pharmacies that make and sterilise them, private fees apply, and blood tests are used to time the next implant. Their clot risk is not known.
Tablets — estradiol valerate (Progynova) or estradiol (Zumenon), commonly 2–8 mg daily, taken once a day or split into two doses. Other guidance: the 2019 position statement gives 2–6 mg daily, and the Zumenon product information, written for menopause, uses one 2 mg tablet a day Tablets under the tongue — changes how the medicine is absorbed, so only do this if your prescriber has told you to Patches — Estradot or Estraderm MX, changed twice a week. Australian guidance gives a common range of 50–200 micrograms per 24 hours; many prescribers start low and build up every two to three months, which may mean wearing more than one patch at a time Gel — once daily, measured in pumps or sachets. Australian guidance gives one to four pumps of Estrogel (0.75 mg estradiol each) or one to two 1 g Sandrena sachets daily. Other guidance: the Estrogel product information, written for menopause, says the long-term safety of more than two pumps a day has not been established Monitoring — oestradiol and total testosterone, rechecked six to eight weeks after any change The three forms of estradiol available in Australia, and how often each is used. From Australia's 2026 standards of care and the TransHub feminising hormones guide, with the 2019 position statement and the Zumenon and Estrogel product information for comparison.
Estradiol tablets and patches are on the PBS with no restriction attached, so the usual co-payment applies. Both estradiol gels, Sandrena sachets and the Estrogel pump, are listed too.
Androgen blockers (anti-androgens) These medicines lower the effect of testosterone. Oestrogen on its own does not usually suppress testosterone enough, so a blocker is often added.
Two are used in Australia: spironolactone and cyproterone acetate. There is no good head-to-head evidence that one is better than the other, so the choice comes down to your health history and how you tolerate it.
The advice is to use the lowest effective dose of cyproterone. The Australian product information reports meningioma with long-term use at doses of 25 mg a day and above, with the risk rising as the total dose taken over the years adds up. If a meningioma is diagnosed, cyproterone must be stopped permanently. Prolactinoma has also been reported.
Bicalutamide, a prostate cancer medicine, is sometimes used as a blocker. Australia's 2026 standards of care say it should not be a first choice, because there is very little evidence for it in gender-affirming care. Liver damage, liver failure and lung damage, including deaths, have been reported, so anyone taking it needs regular liver blood tests for as long as they take it. The Australian product information says most liver changes happen in the first 6 months, and that it is stopped for jaundice or if the liver test ALT rises above twice the upper limit of normal. In July 2026 it added a warning about interstitial lung disease, a lung inflammation that has caused deaths. Bicalutamide is stopped if this is diagnosed. It can make warfarin work more strongly, so anyone on warfarin needs closer INR blood tests, and in rare cases it can make skin burn more easily in the sun.
After an orchidectomy a blocker is no longer needed. Whether to stop hormones before an operation is covered in Hormones around surgery on the Fertility, PrEP and surgery page.
Spironolactone (Spiractin, Aldactone and generics) — a daily tablet, usually 50–200 mg daily in Australian guidance, and 100–200 mg in the 2019 position statement Spironolactone monitoring — it is also a diuretic, so blood tests check electrolytes and kidney function, along with your blood pressure Cyproterone acetate (Androcur, Anterone, Cyproterone Sandoz) — a stronger blocker, and a progestogen in its own right. Australian guidance gives 12.5 mg once a week up to 25 mg daily Cyproterone, lower still — 12.5 mg (a quarter tablet) every second day or twice a week is commonly used Cyproterone monitoring — blood tests usually include liver function Finasteride and dutasteride are not general blockers; they are commonly added for scalp hair loss, although Australian guidance notes it is unclear whether they add benefit Spironolactone and potassium interact. Tell your pharmacist about any potassium supplements, salt substitutes or blood pressure medicines before you start.
Progestogens A separate group of hormones that some people take alongside oestrogen. If one is used, Australia's 2026 standards of care prefer micronised progesterone (for example Prometrium).
The evidence for whether progestogens add anything to breast development or mood is limited, which is why practice varies between prescribers. It is a reasonable thing to ask about.
They are also used the other way around. If periods continue on testosterone and cause distress, the options include raising the testosterone dose, an oral progestogen, or a progestogen-releasing IUD.
Micronised progesterone (Prometrium) — commonly 100–200 mg nightly, reviewed after three to six months No progesterone blood level target is given Testosterone Testosterone is the medicine used in masculinising hormone therapy. In Australia it comes as a long-acting intramuscular injection, a daily gel, a daily cream, and shorter-acting injections.
The gels and cream suit a daily routine, or a dose adjusted in smaller steps. The long-acting injection is given by a clinician every few months.
Testosterone implants (pellets) are used by a small number of people. They last several months, but they are not PBS-subsidised and can only be made by a compounding pharmacy.
On the PBS, every testosterone product needs an Authority prescription. Your prescriber arranges that before you get to the pharmacy.
Why does testosterone need a PBS Authority? Every PBS testosterone product is listed as Authority Required. For gender-affirming care, the prescriber needs a one-off second opinion from an endocrinologist, urologist or sexual health physician. It can be in person or by telehealth, and that specialist's name is then used on later scripts. A script can also be written once an appointment with the specialist is booked. The Authority wording card explains the wording for prescribers and pharmacists.
Which testosterone injections are there? The long-acting testosterone undecanoate injection, 1,000 mg in 4 mL, is on the PBS under four brands: Reandron 1000, Gonadron, Rejunon 1000 and Testosterone ADVZ 1000. Two shorter-acting injections, Primoteston Depot and Sustanon 250, are not PBS-subsidised.
Are there testosterone patches? Not at present. The TGA cancelled the Androderm testosterone patches at the sponsor's request: the 12.2 mg patch from 29 June 2022 and the 24.3 mg patch from 26 June 2025. Australia's 2026 standards of care list testosterone as gels, a cream and injections.
Can testosterone be an e-script? Electronic prescriptions can be used for any medicine anywhere in Australia, and you can still ask for a paper script. An e-script arrives as a token, usually a QR code, by SMS or email.
Testosterone undecanoate (Reandron 1000, and newer brands including Gonadron and Rejunon 1000) — 1,000 mg in 4 mL, deep intramuscular. A second dose about six weeks after the first, then one every 10 to 14 weeks Testosterone 1% gel (Testogel) — a metered pump delivering 12.5 mg per press, or 5 g sachets, applied daily. Australian standards give one to eight pumps, or one to two sachets, daily; four pumps is often enough for full masculinisation Testosterone 2% gel (Testavan), 23 mg per press, one to three presses daily, and 5% cream (AndroForte 5), 1–4 mL daily, often 2 mL Shorter-acting esters — testosterone enantate (Primoteston Depot) and Sustanon, usually 125–250 mg every two to four weeks. Primoteston Depot was removed from the PBS on 1 February 2018 at the manufacturer's request and is now a private prescription; Sustanon is not PBS-subsidised either Monitoring — trough total testosterone and haematocrit; see the blood tests section on the Blood tests and monitoring page How often each form of testosterone is given, compared over fourteen weeks. Intervals from Australia's 2026 standards of care and the Reandron consumer medicine information.
Testosterone can harm a developing pregnancy and does not reliably stop ovulation. If pregnancy is possible for you, contraception is worth a specific conversation with your prescriber — do not assume testosterone covers it.
Puberty blockers (GnRH analogues) These medicines pause puberty by switching off the signal from the brain that drives it. They are given as an implant or a depot injection, always under specialist care.
Australia's standards of care for children and adolescents name goserelin (Zoladex), leuprorelin (Lucrin, Eligard) and triptorelin (Diphereline), repeated every one to six months, depending on the product.
Since 1 October 2026, triptorelin 3.75 mg (Diphereline), a monthly injection, has been on the PBS with no restriction (item 9378N), but its listing carries a note that it "is not for use in gender dysphoria in minors". So, like goserelin and leuprorelin, which are PBS-listed only for other conditions, it is a private prescription for puberty suppression. SA Health's model of care (2023) notes that a young person who cannot get them through a hospital faces a cost of several thousand dollars a year.
Access to goserelin has been changing. The 3.6 mg implant was due to leave the PBS on 1 November 2026, with a free Zoladex Continuity Program planned in its place. On 23 September 2026 the sponsor, AstraZeneca, said instead that the implant will stay on the PBS until 1 May 2027, that PBS prescriptions written by 30 April 2027 can be filled until 1 May 2028, and that the Continuity Program will not go ahead. It did not leave: in November 2026 it is still PBS-listed, for other conditions only, and the PBS Summary of Changes for 1 November 2026 lists no change to it and no deletion notice for 1 December 2026 or 1 January 2027. The 1 May 2027 date is the sponsor's; the PBS has not yet published an end date. If this affects you or your child, ask your prescriber and your pharmacist well before the next dose is due.
From the PBS: the triptorelin listing and the PBS note quoted in this section. Source: Pharmaceutical Benefits Scheme (PBS) Schedule, www.pbs.gov.au, extracted 6 November 2026; reproduced with permission of the Australian Government Department of Health, Disability and Ageing. The rest of this section is GAMSA’s own explanation.
If your medicine is hard to get Shortages happen, and estradiol patches have been the long-running one. The 25, 50, 75 and 100 microgram Estradot patches are still in short supply, with the TGA estimating a return to normal supply by 31 December 2026; the supply page shows the latest position.
The TGA has approved substitution for these patches, so where it is appropriate your pharmacist can supply a different brand or strength that delivers the same amount of estradiol per day, without a new prescription. That approval runs to 28 February 2027.
Ask your pharmacist what is available and whether the product they can get is PBS-subsidised. Bring it up before you run out, not on your last day of supply.
International guidance is explicit that established hormone therapy should be continued rather than stopped, including through periods when your mental health is poor, unless there is a medical reason to stop. Continuity is part of the treatment.
Other medicines used alongside hormone therapy Some effects of hormone therapy have their own treatments: a topical retinoid with benzoyl peroxide, doxycycline or isotretinoin for acne; topical minoxidil or finasteride for scalp hair loss; norethisterone, medroxyprogesterone acetate or a levonorgestrel IUD for periods that continue on testosterone; and low-dose vaginal oestrogen for vaginal dryness. They are not hormone therapy in a different form, and none is automatic.
The add-on therapies page explains each one: why the effect happens, what is usually tried first, and what to ask your prescriber.
References Cheung AS, Wynne K, Erasmus J, Murray S, Zajac JD. Position statement on the hormonal management of adult transgender and gender diverse individuals. Med J Aust. 2019;211(3):127-33. Accessed 17 October 2026. https://www.mja.com.au/journal/2019/211/3/position-statement-hormonal-management-adult-transgender-and-gender-diverse Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022;23(Suppl 1):S1-259. Accessed 24 October 2026. https://doi.org/10.1080/26895269.2022.2100644 AusPATH (Australian Professional Association for Trans Health). Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, version 2 (2026; the document's footer reads "AusPATH SOC 2025"), page 26 (Choice of oestrogen formulation: estradiol implants). First published 1 December 2025; this PDF is dated 30 April 2026. Accessed 24 October 2026. https://auspath.org.au/wp-content/uploads/2026/05/Standards_of_Care_Digital_Final_30_April_2026.pdf AusPATH (Australian Professional Association for Trans Health). Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, version 2 (2026; the document's footer reads "AusPATH SOC 2025"). First published 1 December 2025; this PDF is dated 30 April 2026. Accessed 17 October 2026. https://auspath.org.au/wp-content/uploads/2026/05/Standards_of_Care_Digital_Final_30_April_2026.pdf Zumenon (estradiol) tablets, Australian Product Information, sections 4.2 and 4.4 (date of revision 8 January 2026). Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed 17 October 2026. https://www.safetyandquality.gov.au/medicine-finder/zumenon TransHub (ACON). Hormones — Feminising. Sydney: ACON. Accessed 24 September 2026. https://www.transhub.org.au/medical/hormones-feminising/ Estrogel (estradiol 0.06% w/w) gel, Australian Product Information, section 4.2 (date of revision 18 December 2023). Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed 17 October 2026. https://www.safetyandquality.gov.au/medicine-finder/estrogel Cundill P, Wong P, Cheung A. Hormone therapy prescribing guide for general practitioners working with trans, gender diverse and non-binary patients, version 3.0. Equinox Gender Diverse Health Centre, Thorne Harbour Health; July 2020 (AusPATH-endorsed). Accessed 16 October 2026. https://equinox.org.au/wp-content/uploads/2021/07/ht-prescribing-guideline-v3-aug-2020.pdf Pharmaceutical Benefits Scheme. Estradiol PBS listings — tablets (Progynova, Zumenon), patches (Estradot, Estraderm MX) and Sandrena gel. Accessed 17 November 2026. https://www.pbs.gov.au/medicine/item/1663M Pharmaceutical Benefits Scheme. Estradiol 0.06% gel (Estrogel), PBS item 14719Q. Accessed 17 November 2026. https://www.pbs.gov.au/medicine/item/14719Q Androcur (cyproterone acetate) Australian Product Information and Consumer Medicine Information. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/androcur-tablets AusPATH (Australian Professional Association for Trans Health). Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, version 2 (2026; the document's footer reads "AusPATH SOC 2025"), page 28 (Bicalutamide). First published 1 December 2025; this PDF is dated 30 April 2026. Accessed 24 October 2026. https://auspath.org.au/wp-content/uploads/2026/05/Standards_of_Care_Digital_Final_30_April_2026.pdf AstraZeneca Pty Ltd. Cosudex (bicalutamide) Australian Product Information, section 4.4 Special warnings and precautions for use (liver; coumarin anticoagulants; interstitial lung disease), section 4.5 Interactions (cytochrome P450; warfarin), section 4.8 Adverse effects (photosensitivity reaction) and Summary table of changes. Date of revision 9 July 2026. Accessed 31 October 2026. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=bicalutamide Therapeutic Goods Administration. Product Information safety updates – August 2026 (Cosudex: interstitial lung disease added to section 4.4, approved 8 July 2026). Published 11 September 2026. Accessed 31 October 2026. https://www.tga.gov.au/news/safety-updates/product-information-safety-updates-august-2026 TransHub (ACON). Hormones — Masculinising. Sydney: ACON. Accessed 24 September 2026. https://www.transhub.org.au/medical/hormones-masculinising/ Pharmaceutical Benefits Scheme. Testosterone gel and cream PBS listings — Testogel 1%, Testavan 2%, AndroForte 5 (Authority Required). Accessed 17 November 2026. https://www.pbs.gov.au/medicine/item/10380H Pharmaceutical Benefits Scheme. Testosterone undecanoate 1 g/4 mL modified release injection, PBS item 10205D, General Schedule, Authority Required; brands Gonadron, Rejunon 1000, Reandron 1000 and Testosterone ADVZ 1000. Accessed 17 November 2026. https://www.pbs.gov.au/medicine/item/10205D AusPATH (Australian Professional Association for Trans Health). Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, version 2 (2026; the document's footer reads "AusPATH SOC 2025"), page 33 (PBS authority for testosterone) and page 34 (Table 6. Testosterones). First published 1 December 2025; this PDF is dated 30 April 2026. Accessed 24 October 2026. https://auspath.org.au/wp-content/uploads/2026/05/Standards_of_Care_Digital_Final_30_April_2026.pdf Therapeutic Goods Administration. Androderm testosterone 12.2 mg per patch transdermal drug delivery system sachet (ARTG 61818), cancelled under Section 30(1)(c) of the Act, date of effect 29 June 2022. Cancellations by sponsors. Accessed 24 October 2026. https://www.tga.gov.au/resources/cancellations-by-sponsors/androderm-testosterone-122-mg-patch-transdermal-drug-delivery-system-sachet-cancelled-under-section-301c-act Therapeutic Goods Administration. Androderm testosterone 24.3 mg per patch transdermal drug delivery system sachet (ARTG 82398), cancelled under Section 30(1)(c) of the Act, date of effect 26 June 2025. Cancellations by sponsors. Accessed 24 October 2026. https://www.tga.gov.au/resources/cancellations-by-sponsors/androderm-testosterone-243-mg-patch-transdermal-drug-delivery-system-sachet-cancelled-under-section-301c-act Department of Health, Disability and Ageing. Electronic prescribing (date last updated 9 July 2026). Accessed 24 October 2026. https://www.health.gov.au/our-work/electronic-prescribing Reandron 1000 (testosterone undecanoate 1000 mg/4 mL) injection, Australian Product Information and Consumer Medicine Information. Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed 17 October 2026. https://www.safetyandquality.gov.au/medicine-finder/reandron-1000 OUTinPerth. PBS to remove common testosterone hormone replacement therapy (Department of Health: Primoteston Depot "will be deleted from the Pharmaceutical Benefits Scheme (PBS) on 1 February 2018"; "Deletion from the PBS was requested by the manufacturer"). 15 January 2018. Accessed 17 October 2026. https://outinperth.com/?p=71290 Cundill P. Hormone therapy for trans and gender diverse patients in the general practice setting. Aust J Gen Pract. 2020;49(7):385-90. Accessed 17 October 2026. https://www1.racgp.org.au/getattachment/d0c29d2a-ee67-4ef0-a125-65c2694f3cb2/Hormone-therapy-for-trans-and-gender-diverse-patie.aspx Telfer MM, Tollit MA, Pace CC, Pang KC. Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, version 1.4 (appendices 3 and 4: goserelin, leuprorelin and triptorelin). Melbourne: The Royal Children's Hospital; 2023. Accessed 2 November 2026. https://www.rch.org.au/uploadedFiles/Main/Content/adolescent-medicine/230242%20RCH%20Gender%20Standards%20Booklet%201.4_Nov%202023_WEB.pdf Pharmaceutical Benefits Scheme. Triptorelin 3.75 mg injection (Diphereline), PBS item 9378N — General Schedule, no restrictions from 1 October 2026; PBS note: "The listing of this medicine is not for use in gender dysphoria in minors." Accessed 17 November 2026. https://www.pbs.gov.au/medicine/item/9378N SA Health. State-wide Gender Diversity Model of Care, version 1.2. Adelaide: Department for Health and Wellbeing, Government of South Australia; July 2023. Accessed 24 September 2026. https://www.sahealth.sa.gov.au/wps/wcm/connect/d70c3a24-a054-4f6a-b56c-17152faa9d5c/Model+of+care_Gender+Diversity_Jul2023_FINAL_FOR+PUBLICATION.pdf?MOD=AJPERES Pharmaceutical Benefits Scheme. Update on access to goserelin 3.6 mg implant (Zoladex Implant). Canberra: Department of Health, Disability and Ageing; 16 July 2026. Accessed 24 September 2026. https://www.pbs.gov.au/news/2026/07/update-on-access-to-goserelin-3-6-mg-implant-zoladex-implant AstraZeneca Australia. AstraZeneca to extend PBS access to Zoladex (goserelin) monthly (3.6mg) implant (media release): PBS-listed until 1 May 2027; PBS prescriptions written by 30 April 2027 can be filled until 1 May 2028; the Zoladex continuity program will not proceed. Macquarie Park: AstraZeneca; 23 September 2026. Accessed 23 October 2026. https://www.astrazeneca.com.au/news/media-releases/2026/ASTRAZENECA-TO-EXTEND-PBS-ACCESS-TO-ZOLADEX-goserelin-MONTHLY-3_6mg-IMPLANT.html Pharmaceutical Benefits Scheme. Summary of Changes, 1 October 2026: triptorelin 3.75 mg (9378N) changed from restricted to unrestricted, with a note added; advance notices of deletions for 1 November 2026 (goserelin is not listed). Canberra: Department of Health, Disability and Ageing. Accessed 17 October 2026. https://www.pbs.gov.au/changes Pharmaceutical Benefits Scheme. Summary of Changes, 1 November 2026: no change to goserelin 3.6 mg implant (1454M) or triptorelin 3.75 mg (9378N); advance notices of deletions for 1 December 2026 and 1 January 2027 do not include goserelin. Canberra: Department of Health, Disability and Ageing. Accessed 6 November 2026. https://www.pbs.gov.au/changes Therapeutic Goods Administration. About the shortage of transdermal HRT patches (last updated 14 September 2026). Canberra: TGA. Accessed 17 October 2026. https://www.tga.gov.au/safety/shortages-and-supply-disruptions/medicine-shortages/major-or-ongoing-medicine-shortages/about-shortage-transdermal-hrt-patches Therapeutic Goods Administration. Substitution approval extended for HRT patch shortages (Serious Scarcity Substitution Instrument, in force to 28 February 2027). Canberra: TGA. Accessed 24 September 2026. https://www.tga.gov.au/safety/shortages-and-supply-disruptions/medicine-shortages/medicine-shortage-alerts/substitution-approval-extended-hrt-patch-shortages Men's Regaine Extra Strength Foam (minoxidil 5% w/w), Australian Consumer Medicine Information. ACSQHC Medicine Finder. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/mens-regaine-extra-strength-foam Finasteride GH 1 (finasteride 1 mg) tablets, Australian Consumer Medicine Information. Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/finasteride-gh-1-tablets Primolut N (norethisterone) 5 mg tablets, Australian Consumer Medicine Information. Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/primolut-n Depo-Provera (medroxyprogesterone acetate 150 mg/mL) injection, Australian Consumer Medicine Information. Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/depo-provera Mirena (levonorgestrel 52 mg) intrauterine device, Australian Consumer Medicine Information. Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/mirena-intrauterine-device Vagifem Low (estradiol 10 microgram) modified release vaginal pessary, Australian Consumer Medicine Information. Australian Commission on Safety and Quality in Health Care Medicine Finder. Accessed September 2026. https://www.safetyandquality.gov.au/medicine-finder/vagifem-low Written and reviewed by Theodore South, BPharm (Hons), registered pharmacist. Last reviewed 11 November 2026.